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Abstract: Elderly people represent a patient population at high thromboembolic risk, but 
also at high hemorrhagic risk. There is a general tendency among physicians to underuse 
anticoagulants in the elderly, probably both because of underestimation of thromboembolic 
risk and overestimation of bleeding risk. The main indications for anticoagulation are venous 
thromboembolism (VTE) prophylaxis in medical and surgical settings, VTE treatment, atrial 
ﬁ  brillation (AF) and valvular heart disease. Available anticoagulants for VTE prophylaxis and 
initial treatment of VTE are low molecular weight heparins (LMWH), unfractionated heparin 
(UFH) or synthetic anti-factor Xa pentasaccharide fondaparinux. For long-term anticoagulation 
vitamin K antagonists (VKA) are the ﬁ  rst choice and only available oral anticoagulants nowadays. 
Assessing the beneﬁ  t-risk ratio of anticoagulation is one of the most challenging issues in the 
individual elderly patient, patients at highest hemorrhagic risk often being those who would 
have the greatest beneﬁ  t from anticoagulants. Some speciﬁ  c considerations are of utmost 
importance when using anticoagulants in the elderly to maximize safety of these treatments, 
including decreased renal function, co-morbidities and risk of falls, altered pharmacodynamics 
of anticoagulants especially VKAs, association with antiplatelet agents, patient education. Newer 
anticoagulants that are currently under study could simplify the management and increase the 
safety of anticoagulation in the future.
Keywords: anticoagulation, elderly patients, venous thromboembolism, hemorrhagic risk, 
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Introduction
Anticoagulants are one of the most frequently prescribed medications in elderly patients. 
Indeed, the prevalence of medical conditions representing a risk for thromboembolic 
complications and requiring antithrombotic therapy increases with age. For instance, 
the prevalence of atrial ﬁ  brillation increases dramatically with age, from 5% in people 
aged 65 years and older to approximately 10% in those over the age of 80 years.1 In 
this review, we will ﬁ  rst present the main indications for anticoagulation. Then we 
will go through the different therapeutic options. Finally, we will emphasize speciﬁ  c 
important precautions that need to be observed when prescribing anticoagulants in 
the elderly, and discuss some future perspectives represented by new anticoagulant 
agents that are currently under study.
Indications for anticoagulation
Venous thromboembolism (VTE) prophylaxis
Incidence rates of VTE increase exponentially with age.2 In a recent epidemiological 
study of hospitalized patients in the United States, the incidence ratios of deep vein 
thrombosis (DVT) and pulmonary embolism (PE) were of 4.72 (95% CI 4.30–5.14) 
and 6.2 (95% CI 5.74–6.65) in elderly patients ( 70 years) compared to younger 
patients.3 This could be partly explained by the fact that the prevalence of comorbidities Clinical Interventions in Aging 2009:4 166
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contributing to VTE risk such as malignancy or heart failure 
increases with age. Also, recovery of full mobility after 
an acute illness is much slower in the elderly compared to 
younger adults.
Attempts have been made at deﬁ  ning among elderly 
medical inpatients higher risk subgroups being most likely to 
beneﬁ  t from VTE prophylaxis. Independent risk factors have 
been identiﬁ  ed including restriction of mobility, age   75 
years, history of DVT or PE, chronic edema of lower limbs, 
acute heart failure, paresis or paralysis of a lower limb, 
infectious or rheumatic disease.4,5 For surgical patients, the 
incidence of VTE seems to be more related to the type of 
surgery and comorbidities (especially malignancy) than to 
age. It is therefore important that the overall increased risk of 
VTE in the elderly be taken into account by physicians. The 
under-use of VTE primary prophylaxis in the elderly seems 
to be based mainly on fear of a higher bleeding tendency than 
on facts.6,7 As a whole, if some precautions are observed (as 
will be discussed below), beneﬁ  ts of VTE prophylaxis often 
outweigh its risks. The Evidence-Based Clinical Practice 
Guidelines of the American College of Chest Physicians 
(ACCP) for VTE prophylaxis are summarised in Table 1.8
Venous thromboembolism (VTE) 
treatment
For patients with objectively confirmed DVT or PE, 
anticoagulation in the therapeutic range is indicated and should 
be initiated without delay unless there is an absolute contra-
indication. Initial treatment consists of low molecular weight 
heparin (LMWH), the nowadays available synthetic anti-factor 
Xa pentasaccharide (fondaparinux), or unfractionated heparin 
(UFH) in case of severe renal insufﬁ  ciency, overlapped and 
followed by an oral vitamin K antagonist (VKA).
The duration of anticoagulation after a thromboembolic 
event should be dictated by the balance between protection 
from VTE recurrence by treatment and hemorrhagic risk 
on treatment. Recommended duration of anticoagulation 
varies between guidelines. For VTE associated with 
transient reversible risk factors (such as trauma or surgery), 
the latest ACCP guidelines recommend 3 months of 
anticoagulation.9 Indeed, studies conducted in the 1990s 
showed that 3 to 6 months offer a better protection against 
VTE recurrence than 4 to 6 weeks.10,11 In case of recurrent 
VTE events, long-term anticoagulation is recommended. 
Schulman et al demonstrated an 18.1% (p   0.001) absolute 
reduction of VTE recurrence rate on long-term versus 
6 months of anticoagulation after a second episode of 
VTE, associated with a non-signiﬁ  cant trend for increase in 
major bleeding after 4 years of follow-up.12 In patients with 
VTE and cancer, LMWH are more effective than VKA. 
Ideally, LMWH should be the treatment of choice for the 
initial 3 to 6 months, followed by either VKA or LMWH 
until the cancer is resolved.9,13 More difﬁ  cult and challeng-
ing is to deﬁ  ne the duration of anticoagulation in case of 
unprovoked (also called idiopathic) VTE events and this 
issue remains a matter of debate. In these patients without 
any transient risk factor, the ACCP recommends “at least 
3 months” of anticoagulation, with all patients being evalu-
ated for risk-beneﬁ  t ratio of long term oral anticoagulation to 
prevent recurrent VTE.9 This recommendation is somehow 
difﬁ  cult to apply in clinical practice. Attempts have been 
made at identifying risk factors for VTE recurrence using 
Table 1 Levels of venous thromboembolism risk and American College of Chest Physicians recommended thromboprophylaxis in 
hospitalized patients8
Level of risk Approximate DVT risk 
without thromboprophylaxis, %
Suggested thromboprophylaxis 
options
Low risk
   Minor surgery in mobile patients
   Medical patients who are fully mobile
 10% No speciﬁ  c thromboprophylaxis, 
early and aggressive ambulation
Moderate risk
   Most general, open gynecologic 
or urologic surgery patients
   Medical patients at bed rest or sick
10%–40% LMWH or low-dose UFH 
(bid or tid) or fondaparinux
High risk
   Hip or knee arthroplasty, hip fracture surgery
   Major trauma, spinal cord injury
40%–80% LMWH or fondaparinux or oral 
vitamin K antagonist (INR 2.0–3.0)
Notes: For patients with moderate or high thromboembolic risk and high bleeding risk, mechanical prophylaxis with intermittent pneumatic compression devices, or venous 
foot pump and/or graduate compression stockings are recommended.
Abbreviations: DVT, deep vein thrombosis; INR, international normalized ratio; LMWH, low molecular weight heparins; UFH, unfractionated heparin.Clinical Interventions in Aging 2009:4 167
Anticoagulants in elderly patients
clinical, biological or ultrasonographic characteristics. 
Some predictive elements include age (HR 1.17 per decade 
increase), BMI (HR 1.24 per 10 point increase), malignant 
neoplasm (HR 2.2–4.2),14 residual vein thrombosis (HR 2.4),15 
antiphospholipid antibody syndrome (HR 4.0).16 On the other 
hand, Palareti et al showed that following a ﬁ  rst idiopathic 
DVT, a D-dimer level of   500 μg/L measured 1 month 
after discontinuation of anticoagulation was predictive of 
a low recurrence risk (6.2% over 18 months compared to 
15% for patients with D-dimer   500 μg/L).17 However, this 
interesting ﬁ  nding does not seem applicable to the elderly in 
order to identify lower risk patients because the probability 
of having normal D-dimer level in this population is low. 
In the absence of a clinical prediction rule, an individual 
tailoring of treatment is necessary. Anticoagulation is indeed 
very effective in preventing VTE, with very low recurrence 
rates of 1.3%/year16 and 2.6%/4 years12 in two studies on 
long-term anticoagulation, but at the expense of increased 
bleeding risk. Low-intensity anticoagulation regimens (with 
a target international normalized ratio [INR] of 1.5–1.9) 
have thus been studied. They were found to be less efﬁ  cient 
than conventional-intensity anticoagulation with an INR of 
2.0–3.0 (recurrent VTE rate 1.9/100 patients-years vs 0.7/100 
patient-years; HR 2.8) but superior to placebo (recurrent 
VTE rate 2.6/100 patient-years vs 7.2/100 patient-years, 
HR 0.36).18,19 Although hemorrhagic risk was comparable 
in low-intensity and conventional-intensity regimen groups 
in the study by Kearon et al18 the bleeding rates in this study 
were extremely low in both groups (and different from the 
usual bleeding rates mentioned in other studies) and probably 
not representative of real clinical practice. Therefore, in 
patients with signiﬁ  cant hemorrhagic risk in whom long 
term anticoagulation is considered because of estimated 
high VTE recurrence risk, reducing intensity to an INR of 
1.5 to 1.9 (after the initial 3 months of anticoagulation with 
a target INR of 2.0–3.0) could represent an option in order 
to reduce bleeding risk while maintaining some protective 
effect against VTE recurrence.
Atrial ﬁ  brillation (AF)
The prevalence of atrial fibrillation (AF) increases 
dramatically with age, reaching approximately 10% in people 
over 80 years of age.1 Atrial ﬁ  brillation is responsible for 15% 
of ischemic strokes in the US.20 Among AF patients who are not 
on anticoagulant treatment, the incidence of ischemic stroke is 
about 4.5% per year, decreasing to 1.4% in patients who are on 
adjusted-dose VKA (NNT = 32).21 Several risk stratiﬁ  cation 
schemes have been proposed to identify AF patients at high 
thromboembolic risk. A recent work by Fang et al compared 
five risk stratification schemes applied to the ATRIA 
(AnTicoagulation and Risk Factors In Atrial Fibrillation) 
study cohort. The authors concluded that all schemes had 
discriminatory ability to predict thromboembolism, but the 
ability was relatively low for all.22 However, in the absence 
of more powerful schemes, the widely used CHADS2 score 
(Table 2) remains a very useful tool in daily practice for strati-
fying the risk of thromboembolic complications in elderly 
patients with nonvalvular AF, especially when assessing the 
risk-beneﬁ  t ratio of anticoagulation. Furthermore, this score 
has been validated prospectively in a cohort of 1733 patients 
aged 65 to 95 years.23 The ACCP Evidence-Based Clinical 
Practice Guidelines for antithrombotic therapy in AF are 
summarised in Table 3.24
Valvular heart disease
Indication for long-term anticoagulation is well established 
for prosthetic heart valves because of the high risk of systemic 
embolism. This is illustrated by an annual incidence of 
thromboembolic events for St Jude prosthetic heart valves of 
12% for the aortic position and 22% for the mitral position.25 
The latest ACCP guidelines recommend anticoagulation 
with a VKA for all mechanical valves. The target INR for 
tilting disk or bileaﬂ  et valves is 2.5 (2.0–3.0) in the aortic 
position and 3.0 (2.5–3.5) in the mitral position. Because of 
the higher thromboembolic risk associated with caged ball 
(Starr) or caged disk prosthetic valves, the recommended 
target INR is 3.0 (2.5–3.5) for these valves. In the presence 
of additional risk factors (such as AF, hypercoagulable state, 
low ejection fraction, left atrial enlargement), a target INR 
of 3.0 (2.5–3.5) is recommended, as well as addition of low 
dose aspirin (50–100 mg/day).26
Table 2 Risk of stroke in the National Registry of Atrial Fibrillation 
(NRAF) participants, stratiﬁ  ed by CHADS2 score23
CHADS2 scorea Adjusted stroke rate per 
100 patient-years (95%CI)
0 1.9 (1.2–3.0)
1 2.8 (2.0–3.8)
2 4.0 (3.1–5.1)
3 5.9 (4.6–7.3)
4 8.5 (6.3–11.1)
5 12.5 (8.2–17.5)
6 18.2 (10.5–27.4)
aCHADS2 score is calculated by adding 1 point for each of the following: recent 
congestive heart failure, hypertension, age   75 years, diabetes mellitus; and 2 points 
for prior stroke or transient ischemic attack.Clinical Interventions in Aging 2009:4 168
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Prophylactic and therapeutic options
Anticoagulant options for VTE prophylaxis include 
unfractionated heparin (UFH), low molecular weight heparins 
(LMWH) and the synthetic anti-factor Xa pentasaccharide 
(fondaparinux). For therapeutic range anticoagulation, 
especially long-term anticoagulation, the ﬁ  rst and until now 
only choice consists of vitamin K antagonists (VKA) because 
of their oral route of administration.
VTE prophylaxis in medical settings
Many trials have evaluated safety and efﬁ  cacy of different 
therapeutic agents for thromboprophylaxis in medical 
and surgical patients. In the MEDENOX trial, enoxaparin 
40 mg was shown to be superior to placebo in acutely ill 
medical patients with a reduction of symptomatic VTE and 
venographically diagnosed asymptomatic DVT from 14.9% 
to 5.5% (NNT = 11) without increasing the risk of adverse 
events. Enoxaparin 20 mg did not show any difference when 
compared to placebo in the same study.27 As demonstrated in 
a subgroup analysis of the MEDENOX study, patients over 
75 years old (approximately 50% of the MEDENOX study 
population) had even a greater beneﬁ  t from enoxaparin 40 mg 
with a reduction of VTE risk from 18.5% to 4.1% (NNT = 7).5 
Comparable efﬁ  cacy of enoxaparin 40 mg with UFH 5000 
IU three times daily in preventing VTE in medical patients 
with heart failure or severe respiratory disease has also been 
demonstrated in a study in which more than 55% of patients 
were  70 years old.28 Another LMWH, dalteparin at once 
daily subcutaneous (sc) dose of 5000 IU was shown to be 
superior to placebo in medical inpatients in the PREVENT 
study with a reduction of the incidence of symptomatic VTE 
and asymptomatic proximal DVT from 4.96% to 2.77% 
(NNT = 45).29 VTE rate in this study was much lower than 
in MEDENOX because of the difference in deﬁ  nition of the 
composite primary endpoint (only symptomatic events and 
asymptomatic proximal DVTs were taken into account in 
PREVENT). A subgroup analysis of the PREVENT study 
performed on patients  75 years (33.3% of the study popula-
tion) showed incidence rates of the same composite endpoint 
of 4.2% vs 8.0% respectively for patients on dalteparin vs 
placebo (NNT = 26) without increasing the risk of major 
hemorrage (1.1% vs 0.7%; p = 0.12).30
The selective inhibitor of factor Xa fondaparinux at once 
daily sc dose of 2.5 mg has also been shown to be effective 
and safe in preventing VTE in medical inpatients  60 years 
old. The incidence of VTE (composite endpoint of DVT 
diagnosed by routine venography and symptomatic VTE) 
was reduced from 10.5% in the placebo group to 5.6% in 
the fondaparinux group (NNT = 20).31
VTE prophylaxis in surgical settings
For prevention of VTE following major orthopedic surgery, 
LMWH are effective and safe as well as fondaparinux.8,32,33 
The latter is thought to be more effective than LMWH 
but may be associated with a slightly higher incidence of 
major bleeds, mainly at surgical site.34,35 In case of extended 
thromboprophylaxis (which is suggested for at least 10 days 
and up to 35 days after total hip replacement or total knee 
Table 3 Antithrombotic therapy in nonvalvular atrial ﬁ  brillation:   American College of Chest Physicians recommendations24
Risk categories Antithrombotic 
recommendation
Gradeb
High risk
   Chronic or paroxysmal AF, with prior 
ischemic stroke, TIA or systemic embolism
   Chronic or paroxysmal AF 
and  2 risk factorsa
Long-term VKA
INR 2.5 (2.0–3.0)
Long-term VKA INR 2.5 (2.0–3.0)
1A
1A
Intermediate risk
   Chronic or paroxysmal AF 
and 1 risk factor*
Long-term VKA INR 2.5 (2.0–3.0) 
or 
Aspirin 75–325 mg/day 
VKA preferred to aspirin
1A
1B
2A
Low risk
   Chronic or paroxysmal AF 
and age   75 years and no risk factorsa
Long-term aspirin 75–325 mg/day 1B
aRisk factors: age   75 years; hypertension; diabetes mellitus; moderately/severely impaired left ventricular systolic function and/or heart failure. bGrade 1 (strong recommendation): 
guideline developers are very certain that beneﬁ  ts do outweigh risks, burden and costs. Grade 2 (weaker recommendation): guideline developers are less certain of the magnitude 
of beneﬁ  ts and risks, burden and costs. Support for these recommendations comes from high-quality, moderate-quality or low-quality evidence (labelled A, B and C).74
Abbreviations:   AF, atrial ﬁ  brillation;   TIA, transient ischemic attack;   VKA, vitamin k antagonists.Clinical Interventions in Aging 2009:4 169
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replacement) vitamin K antagonists with a target INR of 2.0 
to 3.0 are an alternative.8
In general, for VTE prophylaxis LMWH and fondaparinux 
should be preferred to UFH whenever possible because of lower 
risk of heparin-induced thrombocytopenia (HIT) with LMWH 
and virtually no risk of HIT with fondaparinux (see below).
VTE treatment
The objectives of anticoagulant therapy in established VTE 
are prevention of thrombus extension, VTE recurrence (early 
and late) and post-thrombotic syndrome. Anticoagulation 
should therefore be started promptly when VTE diagnosis 
is established, or even before diagnosis conﬁ  rmation when 
clinical probability is high. There are several options for 
the initial treatment of VTE: subcutaneous (sc) LMWH, sc 
fondaparinux, intravenous (iv) or sc UFH with monitoring, 
or weight-based sc UFH without monitoring.36 In a recent 
systematic review comparing weight-adjusted ﬁ  xed dose 
sc LMWH to adjusted iv UFH, LMWH were associated 
with fewer thrombotic complications (3.6% versus 5.4%), 
less major bleeding (1.2% versus 2.0%) and lower rate of 
death (4.5% versus 6.0%), all results being statistically 
significant.37 However, LMWH dose adjustment and 
laboratory monitoring are needed in patients with renal 
failure as will be discussed below.
Fondaparinux has also been evaluated for initial treatment 
of VTE in the Matisse trials. The Matisse DVT study38 
compared with a double-blinded design once daily sc 
fondaparinux 7.5 mg (5.0 mg in patients weighing  50 kg 
and 10.0 mg in patients weighing  100 kg) to twice daily 
sc enoxaparin 1 mg/kg given for at least 5 days and until 
an INR greater than 2.0 was reached by VKA. There were 
no differences in the incidence of symptomatic recurrent 
VTE (3.9% for fondaparinux versus 4.1% for enoxaparin), 
major bleeding (1.1% versus 1.2%) or death (3.8% vs 3.0%) 
between the 2 groups during the 3-month study period. The 
Matisse PE study39 compared with an open-label design once 
daily sc fondaparinux 7.5 mg to continuous iv UFH (with 
a target activated partial-thromboplastin time to control 
value of 1.5–2.5) given for at least 5 days and until an INR 
greater than 2.0 was reached by VKA. Again, there were 
no signiﬁ  cant differences in rates of symptomatic recurrent 
VTE (3.8% vs 5.0%), major bleeding (1.3% versus 1.1%) or 
death (5.2% versus 4.4%). Mean age of patients in these two 
studies was between 61 and 63 years old ± 16, and patients 
with a serum creatinine level above 177 umol/L (2.0 mg/dL) 
were excluded, so these results may not be directly applicable 
without speciﬁ  c precautions in the elderly (see below).
Why should we use fondaparinux instead of LMWH? 
Two elements can be pointed out. First, the risk of HIT with 
fondaparinux approaches zero, with only one case-report,40 
and therefore, monitoring of platelets is not recommended. 
It has even become one of the few recommended molecules 
for the treatment of HIT (grade IIC), based on the absence 
of cross-reaction with heparin-PF4 antibodies and clinical 
experience.41,42 Furthermore, this molecule is synthesized, 
in comparison to UFH or LMWH that are extracted from 
animal tissue. Although no infectious contamination has 
ever been described, this could be viewed as an advantage, 
especially in regard to the numerous anaphylactoid reactions 
due to the contamination of heparin by chondroin sulphate 
in heparin in 2008.43 Like other anticoagulants, bleeding is 
the most common serious complication of fondaparinux, 
and this could be a potential limit in elderly patients, in 
particular as no antidote exists. However, in case of major 
bleeding, most authors recommend the use of recombinant 
factor VIIa, which can reverse the anticoagulant effect in 
healthy volunteers.44
Idraparinux is another synthetic pentasaccharide that 
indirectly inhibits factor Xa. It differs from fondaparinux 
in its substantially longer half-life, with a 2.5 mg weekly sc 
dose in studies, and seemed promising in phase II studies. 
The Van Gogh Investigators published two randomized 
open-label noninferiority trials in 2007 that compared the 
efﬁ  cacy and safety of 3 to 6 months idraparinux to standard 
therapy (UFH or LMWH followed by VKA) in patients with 
DVT and PE.45 Although the results satisﬁ  ed the prespeciﬁ  ed 
non-inferiority requirement in the DVT study, idraparinux 
proved to be less efﬁ  cient in PE patients: recurrent VTE was 
higher in the idraparinux group than in the standard treat-
ment group at 3 months (3.4% versus 1.6%) and 6 months 
(4.0% versus 2.0%). Valid explanations for the difference of 
efﬁ  cacy of idraparinux after a DVT and a PE are difﬁ  cult to 
formulate. One hypothesis suggests that the early treatment 
with a long half-life drug and no charging dose could not 
cover the higher early recurrence risk after PE.
Whichever parenteral anticoagulant is chosen for the 
initial treatment of VTE, vitamin K antagonists should 
be started on the same day. The parenteral agent can then be 
discontinued after 5 days, provided the INR is  2.0 for at 
least 24 hours.9
Atrial ﬁ  brillation and valvular 
heart disease
As patients with AF or valvular heart disease have an 
indication for anticoagulation on a long term basis, oral Clinical Interventions in Aging 2009:4 170
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vitamin K antagonists are the drug of choice, and warfarin 
is the molecule used in most clinical trials in these patients. 
A recent study compared warfarin with a target INR of 2.0 
to 3.0 to aspirin 75 mg/day for stroke prevention in elderly 
patients.46 Patients in this study were  75 years with a 
mean age of 81.5 years ± 4.2 years. The primary endpoint 
was a composite of fatal or disabling stroke (ischemic 
or hemorrhagic), intracranial hemorrhage or clinically 
signiﬁ  cant systemic embolism. Analysis was performed on an 
intention-to-treat basis. The yearly incidence of the primary 
endpoint was 1.8% in the warfarin group and 3.8% in the 
aspirin group (RR 0.48, 95% CI 0.28–0.80, p = 0.003). The 
incidence of ischemic stroke was 0.8% versus 2.5% (RR 
0.30, 95% CI 0.13–0.63, p = 0.0004) and hemorrhagic stroke 
0.5% versus 0.4% (RR 1.15, 95% CI 0.29–4.77, p = 0.83). 
The effect of crossovers between the two groups in this 
study may have altered the results concerning hemorrhagic 
risk, but this effect was estimated to be small by the authors 
as there were no differences in either intention-to-treat or 
on-treatment analyses.
Overall, anticoagulation is considered to be more effective 
than aspirin in elderly patients with AF in preventing stroke, 
provided there are no contraindications to anticoagulation and 
the patient decides that beneﬁ  ts are worth the inconvenience 
of long term oral anticoagulation.
Special considerations 
when prescribing anticoagulants 
in the elderly
Hemorrhagic risk
Bleeding is the major complication of anticoagulants. The risk 
of bleeding is dependent on many factors including intensity 
of anticoagulation and patient’s intrinsic characteristics. 
For anticoagulation in the therapeutic range, patient’s age 
represents an independent risk factor for bleeding with all 
anticoagulation modalities.47
UFH
In their study on UFH for initial treatment of DVT, Campbell 
et al showed an increased rate of bleeding and major bleeding 
in patients  72 years, compared with those under 72 years 
(14.1% versus 7.1% for bleeding and 11.1% versus 3.1% for 
major bleeding).48 They also observed that elderly patients 
required lower doses of heparin to achieve therapeutic aPTT 
levels, and had higher plasma heparin levels at standard doses 
of UFH (not adjusted to weight). Factors believed to alter 
pharmacodynamics of heparins in elderly include changes in 
coagulation factors with age, body weight and composition. 
Furthermore, in addition to binding to antithrombin to achieve 
their anticoagulant effect, heparins bind to numerous other 
plasma proteins and cellular components. The variability 
of these determinants of heparins’ distribution volume also 
contributes to the variability of response among patients.49 
To minimize risks of overanticoagulation with UFH, it 
is recommended to use a weight-adjusted dosing pattern. 
For initial treatment of VTE, an initial iv bolus of 80 IU/
kg is recommended followed by a continuous infusion at 
18 IU/kg/h.9 Then, the dose should be adjusted according to 
aPTT level (target aPTT ratio of 1.5–2.5).
LMWH and fondaparinux
As already mentioned above, LMWH should be preferred 
to UFH not only because of much lower rates of heparin-
induced thrombocytopenia, but also because of overall 
lower bleeding risk. In the Cochrane Database systematic 
review mentioned above, van Dongen et al demonstrated a 
signiﬁ  cantly lower risk of major bleeding with LMWH than 
with UFH (1.2% versus 2.0%) when used in VTE treatment.37 
This could be explained by higher bioavailability and more 
predictable anticoagulant response of LMWH compared to 
UFH due to their lesser avidity of binding to plasma proteins.49 
Fondaparinux was shown to be associated with higher risk 
of major bleeding at prophylactic dose of 2.5 mg/day than 
enoxaparin (40 mg/day or twice daily 30 mg) in major 
orthopedic surgery (2.7% versus 1.7%) in the meta-analysis 
by Turpie et al but this difference was mainly attributed to 
surgical site bleeding.34 In Matisse trials, at therapeutic dose 
of 7.5 mg/day, bleeding risk of fondaparinux was comparable 
with therapeutic doses of UFH or LMWH (major bleeding 
rate of 1.1%–1.3% for all three substances).38,39
In elderly patients, to avoid excessive anticoagulation 
with LMWH/fondaparinux and reduce bleeding risk, special 
attention should be given to assessing renal function before 
prescribing LMWH and fondaparinux as will be discussed 
below.
VKA
Warfarin is currently the most extensively prescribed oral 
anticoagulant agent world-wide. The fear of bleeding compli-
cations is a major concern, and the narrow therapeutic range, 
individual variable dose-response and numerous interactions 
with other medications can represent challenges in maintaining 
a safe and stable level of anticoagulation with VKA. Some of 
the determinants of anticoagulant response which have clinical 
relevance in the elderly will be discussed later in this section.Clinical Interventions in Aging 2009:4 171
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In clinical studies with careful monitoring of anticoagulant 
intensity, treatment with VKA increases the risk of major 
bleeding by 0.3 to 0.5%/year and the risk of intracranial 
hemorrhage by 0.2%/year compared to patients without VKA. 
However, higher (but variable) rates have been reported in 
patients on VKA in clinical routine practice, especially in 
the elderly.47 Fang et al showed an increased risk of major 
hemorrhage, particularly intracranial hemorrhage (ICH) in 
patients with AF   80 years whether or not they were on 
warfarin. Although patients on warfarin in this observational 
study may have been represented by low bleeding risk 
patients, the authors concluded that carefully monitored 
anticoagulation with warfarin could be used with safety in 
elderly patients.50 Palareti et al also showed only a tendency 
toward increased overall bleeding on warfarin (prescribed for 
several different indications) in patients  75 years compared 
to those  70 years (9.9% vs 6.6%; p = 0.7), but a signiﬁ  cant 
increase in the risk of intracranial hemorrhage (1.1% vs 0.2%, 
p = 0.05) with age.51 Hylek et al showed higher rates of major 
hemorrhage on warfarin in patients  80 years compared with 
those  80 years (13.1 vs 4.7 per 100 patient-years) during 
the ﬁ  rst year of warfarin therapy, the bleeding rates being 
highest during the ﬁ  rst 3 months of anticoagulation.52 These 
higher rates compared to previous studies can be explained 
by patients’ older age and especially by the fact that the 
majority of patients in other studies were already on warfarin 
before getting included in the studies, therefore representing 
a pre-selected group of “warfarin-tolerant” patients. To better 
assess the hemorrhagic risk during the ﬁ  rst three months of 
anticoagulation, Ruiz-Gimenez et al developed a simple 
bleeding score based on 6 clinical or biological items: history 
of recent bleeding, creatinine, anemia, cancer, clinical PE, 
age  75 years (Table 4).53 It identiﬁ  ed 20% of patients at 
very low risk of bleeding (0.1%–0.3%) at 3 months, and 
another 5% at high risk ( 6% at 3 months). However, this 
score has not been validated in a prospective study, and does 
not evaluate the bleeding risk after 3 months.
One of the major determinants of bleeding associated 
with VKA is the intensity of anticoagulant effect, the risk of 
major bleeding in patients with INR   3.0 being more than 
double the risk of patients with INR between 2.0 and 3.0.47 
In a case-control study, Fang et al identiﬁ  ed an increased risk 
of ICH in patients with an INR of 3.5 to 3.9 compared to 
those with an INR between 2.0 and 3.0 (adjusted odds ratio 
4.5; 95% CI 2.3–9.4).54 In the above-mentioned study by 
Palareti et al increased bleeding risk with supratherapeutic 
INR was also demonstrated, with an exponential increase for 
INR values   4.5 in both age categories.51 In these two latter 
studies, the risk of ICH was not different between patients 
with an INR   2.0 and patients with an INR of 2.0 to 3.0, 
suggesting that well controlled oral anticoagulation does not 
carry a high hemorrhagic risk.
Thus, whenever prescribing oral anticoagulation is 
decided in elderly patients, special attention should be given 
to avoid over-anticoagulation to minimise hemorrhagic 
complications. The beneﬁ  t in terms of bleeding risk in 
reducing anticoagulant intensity is not widely accepted, and 
target INR should be the same as in younger patients (2.0–3.0 
for almost all indications).
Some authors believe there is a tendency among physicians 
to overestimate bleeding risk in elderly patients who would 
be candidates for anticoagulation for AF. One of the 
postulated reasons is that physicians in general feel personally 
responsible for a hemorrhagic complication of anticoagulant 
treatment, as opposed to a thromboembolic complication 
because of absence of treatment.55 Classiﬁ  cation scores have 
been developed to help physicians assess hemorrhagic risk on 
VKA in individual patients. The HEMORR2HAGES score 
Table 4 The RIETE Registry bleeding score53
Risk factors Score
Recent major bleeding 2 points
Creatinine level   1.2 mg/dL (110 μ mol/L) 1.5 points
Anemia (Hb   13 (men) or 12 (women) g/dL) 1.5 points
Cancer 1 point
Clinically overt PE 1 point
Age   75 years 1 point
Rate of major bleeding per 100 patients within 3 months of anticoagulant therapy according to the score:
Score 0 1–4  4
Rate (%, 95%CI) 0.3 (0.1–0.6) 2.6 (2.3–2.9) 7.3 (5.6–9.3)Clinical Interventions in Aging 2009:4 172
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developed by Gage et al56 takes the following bleeding risk 
factors into account: Hepatic or renal disease, Ethanol abuse, 
Malignancy, Older age ( 75 years), Reduced platelet count 
or function, Rebleeding risk, Hypertension (uncontrolled), 
Anemia, Genetic factors, Excessive fall risk, and Stroke, 
giving 1 point to each item apart from Rebleeding risk 
which gets 2 points. The annual incidence of major bleeding 
according to this score is presented in Table 5. Another 
bleeding risk model was also developed for elderly warfarin 
recipients taking into account eight items: age  70 years, 
gender, remote bleeding, recent bleeding, alcohol/drug abuse, 
diabetes, anemia, antiplatelet use. All patients in this latter 
study were  65 years old and 43% were  80 years. The 
rate of major bleeding was 0.9%, 2.0% and 5.4% for groups 
with low, moderate and high risk.57
One of the major difﬁ  culties concerning anticoagulation 
in elderly patients is that those at highest risk for bleeding are 
those who would have highest beneﬁ  t from anticoagulation. 
Thromboembolic and hemorrhagic prediction scores can help 
physicians balance the risk-beneﬁ  t ratio for anticoagulation in 
individual patients. Patient’s preferences should also always 
be taken into account.
Decreased renal function
Renal function decreases gradually with age. As LMWHs 
and fondaparinux are cleared in the urine, assessing renal 
function is of upmost importance when prescribing these 
anticoagulants in the elderly. There is not enough evidence 
in the literature for deﬁ  ning an optimal creatinine clearance 
cut-off under which LMWH should be contra-indicated.58 
Mahe et al assessed the inﬂ  uence of renal function on anti-
factor Xa activity level at prophylactic doses of enoxaparin 
(once daily sc 40 mg) in 125 acutely ill elderly medical 
inpatients (mean age 87.5 years ± 6.3 years). Creatinine 
clearance of  30 mL/min and body weight   50 kg were 
associated with signiﬁ  cantly higher anti-factor Xa levels.59 
However, among patients who had serious bleeding in this 
study (5 patients), anti-factor Xa levels were not higher 
than in patients without bleeding. Although no clinically 
relevant conclusion can be drawn from this study, it seems 
wise to monitor anti-factor Xa level in patients with severely 
decreased renal function even with prophylactic doses of 
LMWH to ensure there is no accumulation.
When treating elderly patients with therapeutic doses 
of LMWH, it is important to keep in mind that even mild 
decreases in creatinine clearance can lead to accumulation of 
LMWHs. Mismetti et al administered daily sc nadroparin at 
180 anti-Xa IU/kg for 6 to 10 days to healthy young (mean 
age 25 ± 4) and elderly (mean age 65 ± 3) volunteers. Body 
weight was similar in both groups. The authors demonstrated 
a signiﬁ  cant accumulation of anti-factor Xa activity in the 
elderly group and no accumulation in the young group, 
with signiﬁ  cant correlations between creatinine clearance 
and clearance of anti-factor Xa activity. Interestingly, 
accumulation occurred in the elderly despite the fact that 
their mean creatinine clearance was not so low (mean 
62 ± 6mL/min vs 114 ± 15mL/min in the young).60 If 
LMWH is prescribed at therapeutic dose in patients with 
renal insufﬁ  ciency, anti-factor Xa monitoring and/or dose 
reduction should be considered. The anti-factor Xa activity 
should be measured 4 hours after a sc. injection (peak 
level). The usually accepted target range for anti-factor Xa 
activity is 0.6 to 1.0 IU/mL for twice-daily administration 
and 1.0 to 2.0 IU/mL for once daily administration. In case 
of severe renal insufﬁ  ciency, UFH should be preferred to 
LMWH.9 Fondaparinux is contra-indicated in patients with 
creatinine clearance  30 mL/min at either prophylactic or 
therapeutic dosage.49 A suggested regimen for the use of 
parenteral anticoagulant in patients with renal insufﬁ  ciency 
is presented in Table 6.
Comorbidities and risk of falls
Several medical conditions are known to increase bleeding risk 
during VKA therapy, including hypertension, cerebrovascular 
disease, ischemic stroke, serious heart disease, diabetes, 
renal insufﬁ  ciency, alcoholism and liver disease.47 Most of 
these conditions have a higher prevalence among elderly 
patients, and should be taken into account while estimating 
risk-beneﬁ  t ratio of oral anticoagulation (see also bleeding 
scores above).
Table 5 Risk of major bleeding on warfarin therapy for AF as 
stratiﬁ  ed by HEMORR2HAGES score56
HEMORR2HAGES 
scorea
Major bleeding per 100 
person-years (95% CI)
0 1.9 (0.6–4.4)
1 2.5 (1.3–4.3)
2 5.3 (3.4–8.1)
3 8.4 (4.9–13.6)
4 10.4 (5.1–18.9)
 5 12.3 (5.8–23.1)
Any score  4.9 (3.9–6.3)
aHEMORR2HAGES score is calculated by adding 1 point for each of the following:
Hepatic or renal disease, Ethanol abuse, Malignancy, Older age ( 75 years), Reduced 
platelet count or function, Rebleeding risk (2 points), Hypertension (uncontrolled), 
Anemia, Genetic factors, Excessive fall risk, and Stroke.Clinical Interventions in Aging 2009:4 173
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Another major concern when prescribing VKA in elderly 
patients is the risk for falls. Gage et al showed an increased 
risk of intracranial hemorrhage (ICH) in patients with AF 
at high risk of falls (based on physician’s documentation 
in patient’s medical record: “frequent falls, history of falls, 
multiples falls, or tendency for falls”) compared to other 
patients (2.8 versus 1.1 per 100 patient-years).61 Prescription 
of warfarin did not affect the incidence rate of ICH, but the 
severity of the hemorrhagic events with a higher 30-day 
mortality in patients on warfarin (51.8% vs 33.6% for those 
without warfarin; p = 0.007). Other independent risk factors 
for ICH in this study were prior stroke, prior major bleeding 
and neuropsychiatric impairment. Nevertheless, patients at 
high risk for falls and thus ICH were at even higher risk for 
ischemic stroke associated with AF (13.7 per 100 patient-
years). Therefore, patients with AF with additional stroke risk 
factors seem to have an overall beneﬁ  t from anticoagulation 
even if they are at high risk for falls.61
Pharmacokinetics and pharmacodynamics 
of   VKAs in the elderly
Warfarin is a drug from the coumarin group and is the most 
widely used VKA worldwide. It is administered orally and 
rapidly absorbed from the gastrointestinal tract. It achieves its 
anticoagulant effect by interfering with vitamin K metabolism, 
thus reducing hemostatically active factors II, VII, IX and X. 
About 99% of warfarin is bound to plasma proteins and it 
is eliminated through metabolism by the liver cytochrome 
P450 CYP2C9.62,63 Factors inﬂ  uencing pharmacokinetics 
of warfarin are not age-speciﬁ  c. They include diminished 
absorption (eg, fat malabsorption, cholestyramine), enzyme 
genetic polymorphisms inﬂ  uencing hepatic metabolism, 
and specially drug interactions at the CYP2C9 level, which 
either can increase or decrease INR level. Drug interactions 
represent a signiﬁ  cant issue in elderly patients on warfarin 
because of polymedication and frequent changes (adding or 
stopping) in concomitant medications related to intercurrent 
acute illnesses.
Elderly patients also show increased pharmacodynamic 
response to warfarin for several reasons: they may have 
decreased synthesis of clotting factors due to liver disease; 
their dietary vitamin K intake (contained mainly in leafy 
green vegetables) may be low, especially in acute medical 
settings, so there is less competitive antagonism to the 
effect of VKA; the level of vitamin K produced by intestinal 
bacteria may be decreased by broad-spectrum antibiotics; 
concomitant use of drugs interacting with platelet function 
including nonsteroidal anti-inﬂ  ammatory drugs (NSAIDS) or 
aspirin is more frequent and increases bleeding risk; hyper-
metabolic states such as fever (probably through increased 
catabolism of vitamin K-dependant clotting factors) may 
increase response to warfarin in greater extent in frail elderly 
patients with poor vitamin K storage.62,63
Because of this higher sensitivity to warfarin in the 
elderly, usual recommended initial doses of warfarin can-
not be applied to this population. Garcia et al pointed out 
the effect of age and sex on warfarin response, and the 
risk of excessive anticoagulation when initiating warfarin 
Table 6 Suggested regimen for the use of parenteral anticoagulants in patients with renal insufﬁ  ciency
Creatinine clearance
(Cockroft)
Prophylactic anticoagulation Therapeutic anticoagulation
 50 mL /min • Fondaparinux •  Fondaparinux
• LMWH • LMWH
30–50 mL/min •  LMWH without dose reduction
•   Fondaparinux without dose 
reduction
•   LMWH without dose reduction, anti-Xa level after 3rd 
or 4th dose, anti-Xa monitoring twice weekly thereafter 
(NB dose reduction can be considered in this group if 
creatinine clearance is at the lower limit)
• UFH
•   Fondaparinux for limited duration of treatment (caution 
in case of prolonged treatment because of the risk of 
accumulation)
 30 mL/min • UFH
•   LMWH with dose reduction 
(1/2 dose), anti-Xa monitoring if 
prolonged treatment (to make 
sure there is no accumulation)
• Fondaparinux  contra-indicated
• UFH
•   LMWH with dose reduction (1/2 dose), anti-Xa level 
after the 2nd dose, and minimum twice weekly thereafter
•  Fondaparinux contra-indicated
Abbreviations: LMWH, low molecular weight heparins; UFH, unfractionated heparin.Clinical Interventions in Aging 2009:4 174
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in elderly ambulatory patients: if warfarin is initiated at 
5 mg/day, 82% of women and 65% of men aged  70 years 
will be overanticoagulated. The authors showed that for 
each year of age, the weekly required warfarin dose was 
reduced by 0.4 mg, and that at any given age, the weekly 
warfarin dose for women was 4.5 mg lower than for men.64 
A specific low-dose regimen has been developed for 
initiating warfarin therapy in medical inpatients  70 years 
and validated prospectively by Siguret et al.65 Mean age of 
the validation sample was 84.6 ± 4.9 and mean body weight 
64 ± 15 kg. Maintenance dose was predicted depending 
on INR level measured on the fourth day, after three daily 
doses of 4 mg of warfarin. The predicted maintenance dose 
of warfarin (3.2 ± 1.6 mg/day) correlated well with actual 
dose (3.1 ± 1.7 mg/day). Therefore, this proposed regimen 
could represent a useful tool for avoiding overanticoagulation 
when introducing warfarin in the elderly (Table 7).
In trying to start and maintain safe and stable anticoagulation 
with VKAs in the elderly, physicians should be aware of 
increased response to warfarin in this age group. Furthermore, 
physicians and patients should keep in mind potential major 
effects of dietary changes and drug interactions (even 
over-the-counter and herbal medicines) on anticoagulation 
intensity. INR should be closely monitored whenever 
changes occur in dietary habits or concomitant medications.62 
Ideally, patient education about oral anticoagulation should 
be part of the therapy as it is the case for diabetic patients. 
Indeed, Kagansky et al identiﬁ  ed poor quality of education 
as a major risk factor for anticoagulation-associated bleeding 
complications in the elderly.66
Association with antiplatelet agents
Because of increased incidence of cardiovascular events 
with age, elderly patients are likely to have indications for 
both oral anticoagulation and antiplatelet therapy, the most 
typical situation being AF associated with ischemic heart 
disease. With the exception of some patients with prosthetic 
heart valves (see above), combination of anticoagulant and 
antiplatelet therapy has not been proven to be superior to 
anticoagulation alone for any other indication, and carries 
a signiﬁ  cantly increased bleeding risk.67 There is persistent 
debate concerning patients on oral anticoagulation who suffer 
from an acute coronary syndrome necessitating percutaneous 
coronary intervention with stent implantations. Some 
authors believe that in this context, selected patients at high 
thromboembolic risk have an overall beneﬁ  t of a triple therapy 
(aspirin and clopidogrel added to their usual anticoagulation 
regime), provided some precautions are observed: avoidance 
of drug eluting stents (complete endothelialisation of bare 
metal stents occurs much more rapidly, thus requiring dual 
antiplatelet therapy after stenting for one month compared to 
6 months at least for drug eluting stents), avoidance of peri-
procedural glycoprotein IIb/IIa inhibitors whenever possible, 
increased frequency of INR monitoring during triple therapy, 
prescription of gastric protection.68
Newer anticoagulant agents
In contrast to the earlier described therapeutic agents, newer 
anticoagulants selectively target speciﬁ  c steps in the coagu-
lation cascade. The farthest along in clinical development 
include agents targeting factor Xa and factor IIa (thrombin). 
Factor Xa is an attractive target as it is positioned at the start 
of the common pathway of coagulation. Thrombin plays a 
central role by converting ﬁ  brinogen to ﬁ  brin, and activating 
other coagulation factors (V, VII, XI, XIII) and platelets.
Indirect Xa inhibitors
Pentasaccharides represent the ﬁ  rst generation of factor Xa 
inhibitors. These synthetic drugs (fondaparinux, idraparinux) 
selectively inhibit factor Xa through their binding to and 
activation of antithrombin and are therefore called indirect 
inhibitors. Their structure is based on the pentasaccharide 
region of the heparin molecule speciﬁ  c for antithrombin 
binding: they lack the longer saccharide chain that neutralizes 
thrombin. They are administered by subcutaneous injection. 
Unlike the heparins, the pentasaccharides bind selectively 
to antithrombin and do not affect platelet function or react 
with heparin-PF4 antibodies. Their use at prophylactic or 
therapeutic doses has been discussed hereabove.
Table 7 Speciﬁ  c low-dose regimen for initiating warfarin therapy 
for patients   70 years65
Day INR value 10 AM Warfarin dose (mg) 6 PM
Day 0 Do not measure 4
Day 1 Do not measure 4
Day 2 Do not measure 4
Predicted maintenance dose
Day 3  1.3 5
INR   1.3 4
INR   1.5 3
INR   1.7 2
INR   1.9 1
INR   2.5 Measure INR daily and omit doses 
until INR   2.5 mg, then give 1 mg
Notes: This algorithm does not apply to patients who have received 
warfarin within the preceding week of have a pretreatment international 
normalized ratio (INR)  1.3.Clinical Interventions in Aging 2009:4 175
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Direct Xa inhibitors
Based on the efﬁ  cacy of fondaparinux, research is directed 
toward the development of oral drugs inhibiting factor Xa. 
These molecules reversibly block the active site of factor 
Xa, without binding to antithrombin (direct inhibitors). This 
allows the inhibition within the assembled prothrombinase 
complex as well as the inhibition of free factor Xa. Two oral 
direct Xa inhibitors are currently ongoing phase III trials 
for treatment of VTE: apixaban and rivaroxaban. Phase II 
studies of apixaban for the treatment of DVT showed low 
recurrence and bleeding rates, warranting a phase III trial. 
The same conclusions were drawn in two phase II studies 
evaluating rivaroxaban, another oral inhibitor.69–71 These 
drugs appear very promising, as they possess two major 
advantages over the current anticoagulation therapies: there 
is no need for close monitoring of the anticoagulant effect, 
and they are administered orally from the beginning of the 
treatment. In the case of solid phase III results and absence of 
toxicity reports, they could supplant the initial treatment with 
LMWH/pentasaccharide and secondary phase with VKA.
Direct thrombin inhibitors
Another way to efﬁ  ciently alter the coagulation system 
is through the direct inhibition of thrombin (factor IIa), 
independently of antithrombin. Current examples include 
hirudin and argatroban, parenteral drugs approved for 
the treatment of HIT. Proof of the efficiency of oral 
molecules was set by trials on the first oral thrombin 
inhibitor studied, ximelagatran. In 2005, the THRIVE 
investigators concluded on the non-inferiority of 6-month 
ximelagatran compared to enoxaparin followed by warfarin 
for proximal DVT.72 This drug also proved to be similar to 
standard anticoagulation in other settings: anticoagulation 
in orthopedic thromboprophylaxis, and stroke prevention 
in atrial ﬁ  brillation. This led to its temporary licensing in 
Europe, until it was eventually withdrawn from the world 
market because of potential hepatic toxicity. However, this 
provided proof that an oral anticoagulant with no need of 
monitoring could be as efﬁ  cacious and safe in terms of major 
bleeding as LMWH followed by VKA after VTE. Currently, 
dabigatran is undergoing phase III trials for the initial and 
long-term treatment of VTE (RE-COVER, RE-MEDY trials). 
So far, its use has not been associated with hepatotoxicty.
The major advantages of this class are the same as of the oral 
direct Xa inhibitors: oral route and predictable anticoagulant 
response without need for coagulation monitoring. One 
drawback is the absence of antidote. Moreover, recombinant 
factor VIIa was shown to have a limited capacity to reverse 
the anticoagulant effect of melagatran.73 Overall, the safety and 
bleeding risk associated with these newer anticoagulants drugs 
in elderly patients will have to be studied in further trials.
Conclusions
Elderly people represent a patient population at high throm-
boembolic risk. However, conditions contributing to higher 
hemorrhagic risk are also more prevalent in this population. 
Thorough knowledge of recommended indications to 
anticoagulation and consideration of the importance of 
thromboembolic risk in this population is important since 
there is a tendency to underuse anticoagulants in the elderly. 
Assessing the beneﬁ  t-risk ratio of anticoagulation is one of 
the most challenging issues in the individual elderly patient, 
patients at highest hemorrhagic risk often being those 
who would have the greatest beneﬁ  t from anticoagulants, 
and some clinical rules represent useful tools in everyday 
clinical practice in this setting. Few guidelines on the use of 
anticoagulants speciﬁ  c for the geriatric patient population 
are available. A practical guideline had been issued by the 
American Geriatrics Society in 2002 based on the 2001 
ACCP evidence-based guidelines. An update is likely to 
be published in the near future following the 2008 ACCP 
evidence-based guidelines to which we refer along our 
review. Elderly patients represent a considerable subset in 
trials on VTE prophylaxis and AF, so the results of these 
studies seem applicable to the geriatric population. However, 
population age in VTE treatment trials is often signiﬁ  cantly 
lower, and further trials speciﬁ  cally considering elderly 
patients are needed. In the meantime, all anticoagulant agents 
can be used in the elderly provided some important speciﬁ  c 
considerations are taken into account in order to maximise 
the safety of this treatment.
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